☆ 4.6 Meeting Abstract

OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses

JOURNAL OF THORACIC ONCOLOGY (2017)

Journal

JOURNAL OF THORACIC ONCOLOGY

Volume 12, Issue 1, Pages S9-S10

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jtho.2016.11.011

Keywords

NSCLC; atezolizumab; Immunotherapy

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.